Non Hodgkin Lymphoma Articles & Analysis: Older
2 articles found
The aim of this new study was to investigate the expression and function of PTGDS in diffuse large b-cell lymphoma (DLBCL), especially the potential role of PTGDS inhibitor AT56 in lymphoma therapy. ...
Gene-modified cell therapies (GMCTs) represent the most effective therapeutic platform for many patients with advanced diseases including relapsed and refractory leukemia, non-Hodgkin lymphoma, and other blood cancers [1]. Specifically, chimeric antigen receptor T cell (CAR-T) therapies targeting CD19 have demonstrated remarkable responses and ...